A calf tissue cage model was used to study the pharmacokinetics (PK) and pharmacodynamics (PD) of oxytetracycline in serum, inflamed (exudate) and noninflamed (transudate) tissue cage fluids. After intramuscular administration, the PK was characterized Based on the potency of oxytetracycline in serum, the predicted 50% TAR single doses required to achieve a bacteriostatic action covering 48-hr periods were 197 mg/kg (M. haemolytica) and 314 mg/kg (P. multocida), respectively, against susceptible populations. Dosages based on the potency of oxytetracycline in broth were 25-and 27-fold lower (7.8 and 11.5 mg/kg) for M. haemolytica and P. multocida, respectively.
| INTRODUCTION
The spectrum of activity of oxytetracycline includes two major bacterial species causing bovine pneumonia, Mannheimia haemolytica and Pasteurella multocida (Nouws, Smulders, & Rappalini, 1990; . Oxytetracycline remains in extensive use for the treatment of calf pneumonia as it possesses the advantage of availability in both low (5%-10%w/v) and high (20%-30%w/v) strength injectable products. The latter provide highdose (20-30 mg/kg) long-acting formulations; single-dose therapy may be clinically effective when these formulations are administered intramuscularly. These depot formulations provide sustained absorption from the intramuscular injection site, leading to flip-flop pharmacokinetics (PK) (Nouws & Vree, 1983; Nouws et al., 1990; Toutain & Raynaud, 1983) . Dosages for oxytetracycline were set many years ago, and it may now be appropriate to re-evaluate them in the light of currently accepted PK/ pharmacodynamic (PD) concepts. Scientifically, the soundest approach to prediction of dosage for antimicrobial drugs (AMDs) is to link PK parameters and variables with an appropriate PD index of potency and efficacy, applying the universal equation for systemically acting drugs:
where dose is the computed dose, Cl = body clearance, F = bioavailability and AUC = area under plasma/serum concentration-time curve (Toutain & Bousquet-Mélou, 2004a ). For those AMDs for which the PK/PD index that best predicts efficacy is AUC 0-24 hr /MIC, such as oxytetracycline in the present investigation (see Results and Discussion), this equation was adapted by Aliabadi & Lees (Aliabadi & Lees, 2001 , 2002 and to:
(1) Dose = Cl × AUC F (2) Dose (per day) = where Cl = body clearance per hr, AUC 0-24 hr /MIC e (in hr) = in vitro ratio of experimentally determined area under the serum or broth concentration-time curve over 24 hr to the minimum inhibitory concentration (MIC e ) of the tested experimental isolates for a target end point (bacteriostatic or bactericidal effect), MIC distribution = distribution of MICs of oxytetracycline from an epidemiological literature survey, f u (from 0 to 1) = fraction of drug not bound to serum protein and F = bioavailability (from 0 to 1). MIC distributions for P. multocida (498 strains) and M. haemolytica (481 strains) were obtained from infected cattle; MICs were measured at the Iowa state Veterinary Diagnostic Laboratory Data from 2000, 2001, 2002 and 2003 (http://vads.vetmed.vt.edu/index.cfm) . From this, it is clear that selection of an optimal dose depends on (i) assessment of both PK (Cl, F, f u, ) and PD (MIC) properties and (ii) determination of an appropriate breakpoint value of the AUC 0-24 hr /MIC ratio for bacteriostatic or bactericidal effect.
The internationally accepted European Union Committee on Antimicrobial Testing (EUCAST) and the Clinical Laboratory Standards
Institute (CLSI, 2004 (CLSI, , 2008 ) methods for MIC determinations are based on the use, almost universally, of nonbiological growth media, such as Mueller-Hinton broth (MHB) (Papich, 2013 (Papich, , 2014 . Whilst such media are specifically formulated to provide optimal in vitro growth conditions, they differ in composition from body fluids. For example, most broths contain small amounts of protein including negligible amounts of albumin, whereas treatment of disease in vivo depends on drug concentration in the biological fluid of the biophase. Concentration in the latter is driven by the plasma concentration of free drug. As the protein bound fraction is microbiologically inactive, it is common to link the free rather than total serum concentration with an in vitro MIC (or MBC) value (f u in Equation 2). A potential problem with this approach is the assumption that the differences in MIC determined in broth, serum and the local biophase milieu are attributable solely to drug protein binding in the latter two fluids. It is potentially flawed additionally, because artificial broths are quantitatively dissimilar to biological fluids in most chemical constituents (not only albumin, to which most drugs bind to some degree) and also in the absence of proteins such as serum complement, which may impact on drug potency. Therefore, bacterial growth and AMD action may commonly differ in differing growth matrices.
For the foregoing reasons, experiments in our laboratory have routinely compared MIC and MBC for calf pathogens in broth and biological fluids (serum, transudate and inflammatory exudate) collected from calves, to provide more biologically relevant growth matrices and to identify any possible matrix effect (Aliabadi, Landoni, & Lees, 2003; Brentnall, Cheng, McKellar, & Lees, 2012; Sidhu, Landoni, Aliabadi, & Lees, 2010) . The latter group reported that protein concentrations in exudate (44.7 g/L) and transudate (40.7 g/L)
were lower than in calf serum 61.9 g/L). For example, for tulathromycin and the bovine pneumonia pathogens, M. haemolytica and P. multocida, serum: broth MIC ratios were of the order of 1:50, despite some 40% binding to serum protein (Illambas, Potter, Rycroft, & Lees, 2009 ).
In stark contrast, for a single strain of M. haemolytica, oxytetracycline MICs (μg/ml) were higher in serum (14.8) exudate (12.8) and transudate (11.2) than in MHB (0.5) (Brentnall et al., 2012) . These marked differences between artificial broth and biological fluids are both drug and microbial species-dependent and cannot be explained by binding to plasma protein.
Determination of PD properties of oxytetracycline in biological matrices is therefore a prerequisite for the use of PK-PD integration and modelling approaches to dose determination, aimed at eradication of bacteria and/or minimizing opportunities for the emergence of antimicrobial resistance (Lees, Aliabadi, & Toutain, 2004; Martinez & Silley, 2010; Mouton et al., 2011; Papich, 2014) . For other drugs, smaller broth serum differences in potency have been reported, but it should be noted that a difference in MIC, between serum and broth, generally regarded as small in microbiological terms, could readily lead, when the objective is prediction of dosage for bacteriological cure in diseased animals, to significant over or under estimation of dose required.
Three integrated PK-PD surrogates for clinical efficacy; maximum serum concentration (C max )/MIC, time of serum concentration exceeding MIC (T > MIC) as a percentage of the interdose interval, area under curve (AUC)/MIC, and the ratio of the area under the plasma/serum concentration-time curve to MIC (in steady-state conditions) have been widely used (Craig, 1998; Frimodt-Moller, 2002; Lees & Shojaee Aliabadi, 2002; Martinez, Papich, & Drusano, 2012; Martinez & Silley, 2010; Mouton, Dudley, Cars, Derendorf, & Drusano, 2002; Mouton et al., 2011; Papich, 2014; Schentag, 2000; Toutain, del Castillo, & Bousquet-Melou, 2002; . This study focusses on AUC/MIC, as oxytetracycline has a long terminal half-life, and it was shown that this index is the most appropriate for any AMD having a long terminal half-life (Nielsen & Friberg, 2013) .
The objectives of this investigation were (i) to establish the serum concentration-time profile and to derive PK data for oxytetracycline in 10 healthy calves after intramuscular administration at the dosage of 20 mg/kg; (ii) to determine the rate and extent of oxytetracycline penetration into and elimination from carrageenan-inflamed (exudate) and noninflamed (transudate) fluids in a tissue cage model; (iii) to integrate these in vivo PK findings with in vitro PD (MIC) data for oxytetracycline against M. haemolytica and P. multocida; (iv) to model in vitro time-kill profiles of oxytetracycline against six isolates each of M. haemolytica and P. multocida in both serum and MHB, in order to generate AUC/MIC breakpoints for each organism to achieve bacteriostatic and bactericidal levels of growth inhibition; and (v) to use the derived PK and PD data, with epidemiological MIC distributions, to calculate, using Monte Carlo simulations, dosages of oxytetracycline for both an empirical (probabilist) therapeutic response, that is taking into account the entire MIC distribution but also considering only susceptible subpopulations of P. multocida and M. haemolytica. Such dual simulations are necessary to investigate the clinical value of an antimicrobial sensitivity test (AST) and also to determine its appropriate numerical value.
Simulations were undertaken for (i) each bacterial species, (ii) two levels of growth inhibition (bacteriostatic and bactericidal) and (iii) both a single dose (efficacious over the subsequent 48 hr) and a maintenance dose administered every 48 hr under steady-state conditions for 50 and 90% target attainment rates (TARs). 
| MATERIALS AND METHODS

| Animals and surgical procedures
| Sampling procedures
Blood samples (10 ml) were collected, protected from light, from a jugular vein, into vacutainers (Becton, Dickinson and Company, Oxford, Oxon, UK) without anticoagulant, prior to and at times of 15, 30 and 45 min and 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 32, 48, 72, 96 and 120 hr after injection of oxytetracycline. Exudate and transudate samples (1.5 ml)
were collected and protected from light, before and at predetermined times of 2, 4, 6, 8, 10, 12, 24, 32, 72, 96 and 120 hr. All samples were centrifuged to remove cells at 2,000 g for 10 min at 4°C, and supernatants were stored at −70°C until analysed for oxytetracycline.
| Analysis of oxytetracycline
A high-pressure liquid chromatography (HPLC) method with ultraviolet detection was used for analysis of oxytetracycline concentrations in serum, exudate and transudate (Brentnall et al., 2012) . All reagents were HPLC grade and obtained from Sigma-Aldrich Chemicals (Poole, Dorset, UK). Chromatographic data were analysed using Chromeleon™ version 6.80 (Dionex Corporation), and concentrations of oxytetracycline were calculated using peak area ratios. Standards were prepared by spiking blank serum, exudate and transudate with oxytetracycline, using eight concentrations over the range 0.1-25 μg/ml (serum) and 0.1-5 μg/ml (exudate and transudate). They were run with every assay to evaluate linearity and reproducibility.
For linearity, r 2 was >.98. The lower limit of quantification (LLOQ) for oxytetracycline in all three fluids was 0.1 μg/ml. The LLOQ had a coefficient of variation of less than 20%, and all other standards were less than 15% of nominal concentration. The intra-and interassay percentage inaccuracies were 3.50% and 9.57%, respectively, at a concentration of 10 μg/ml, 1.43% and 4.78%, respectively, at a concentration of 5 μg/ml and 2.06% and 10.6%, respectively, at a concentration of 0.1 μg/ml.
| Pharmacokinetic analyses
Oxytetracycline concentration-time data in serum, exudate and transudate in individual calves were analysed using the WinNonlin ® re-
View, California, USA). Data for each fluid were submitted to noncompartmental analysis using the statistical moment approach described by Yamaoka, Nakagawa, and Uno (1978) . The linear trapezoidal rule was used to calculate AUC values and area under the first moment curve (AUMC). The mean residence time (MRT) was determined as AUMC/AUC.
| PK-PD integration
The PK-PD surrogates C max /MIC, AUC 0-24 hr /MIC (first 24 hr after dosing) and AUC 0-∞ /MIC were calculated for each fluid (serum, exudate and transudate) harvested in the tissue cage study from 10 calves. Results were expressed as ratios of geometric mean C max , AUC 0-24 hr and AUC 0-∞ for individual calves (n = 10) and geometric mean MIC (n = 6 for each bacterial species). Geometric means were selected for measurements which are lognormally distributed. In addition, the ratios of average serum concentration (C av )/MIC, for four consecutive 24-hr periods after administration of oxytetracycline, were calculated.
| PK-PD modelling of in vitro time-kill data
For six isolates, each of M. haemolytica and P. multocida growth inhibition curves over 24 hr was determined in two matrices, MHB and calf serum, as previously described (Lees et al., 2015) . Ratios of AUC 0-24 hr /MIC were calculated for each of the six isolates of the two organisms at each of the five oxytetracycline concentrations tested (from 0.25 to 4xMIC multiples). AUC 0-24 hr values were computed in terms of MIC multiples (vide infra). The data were modelled to the sigmoidal E max equation (Equation 3) using the nonlinear regression WinNonlin® programme:
where E 0 is the bacterial growth after 24-hr incubation in the absence of oxytetracycline (control samples), expressed as log 10 cfu/ ml subtracted from the initial inoculum log 10 cfu/ml; E max is the maximum antimicrobial growth inhibition determined as the change in log 10 cfu/ml after 24-hr incubation with oxytetracycline; EC 50 is the AUC 0-24 hr /MIC value providing 50% of the maximum antibacterial effect; X is the predictive variable (expressed as AUC 0-24 hr / MIC); and N is the Hill coefficient, which describes the slope of the AUC 0-24 hr /MIC-effect curve. Bacteriostatic (E = 0, no change from initial inoculum count), bactericidal (E = −3, a 3log 10 reduction from initial inoculum count) and E = −4, a 4log 10 reduction from initial inoculum count AUC 0-24 hr /MIC values were determined for each isolate of each organism in MHB and serum. E = −4, a 4log 10 reduction
in count, represents a 10,000-fold decrease from a starting count of 10 7 cfu/ml to a count of 10 3 cfu/ml; therefore, it does not indicate virtual eradication. 
| Dosage determination using a steady-state approach (48-hr dosing interval)
In Equation 2, the term AUC 0-24 hr /MIC (hr) is the experimentally determined PK-PD index to be achieved, expressed as the ratio of area under the serum concentration-time curve over 24 hr to MIC, obtained using a test pathogen for a given bacteriological effect (bacteriostatic, bactericidal or 4log 10 reduction in count). For greater clarity, we replaced the AUC 0-24 hr /MIC ratio in hr, by a more readily understood dimensionless equivalent PD factor: κ PD , (Toutain et al., 2007 Assuming that administration of the dose n + 1 occurs at a time after which the distribution of the previous dose n is complete (pseudosteady-state), the accumulation ratio can be simplified as per
Equation 7: with k 10 expressed in hr −1 and τ is the dosing interval in hr. Therefore, R is dimensionless. For further explanation, see Lees et al. (2015) .
Combining Equations 6 and 7 and assuming PK linearity (clearance identical with two dose levels), the loading dose for 48-hr effect for 
AUC (maintenance dose) .
Dose (loading dose 48 hr)
× Dose (maintenance per 48 hr)
was low. [2000] [2001] [2002] [2003] and are represented in Figure 1a ,b. These distributions reflect the current US situation and prompted us to determine the corresponding susceptible wild-type population; the latter is expected to be the same throughout the world, see Discussion. This wild-type distribution was statistically determined by calculation of the 99.9%
wild-type cut-off values plotted in Figure 1c ,d (Turnidge, Kahlmeter, & Kronvall, 2006) . Only the MIC distribution of wild-type bacteria was included in the simulation, corrected by the experimentally determined value of f u to allow for oxytetracycline protein binding in serum, as the reported MIC literature values were determined in broth. A further correction factor was applied to account for MIC differences between broth and serum for both species. The probabilities of distribution for each dosage estimation were run for 50,000 simulated trials (Figure 2 ). 
| Statistical analyses
| RESULTS
| Pharmacokinetics
The mean (±SEM) concentrations of oxytetracycline in calf fluids after intramuscular administration at a dose rate of 20 mg/kg are 
P.multocida MIC (µg/ml)
Number of isolates (a) (b) (c) (d)
presented in Figure 2 . PK variables are presented in Table 1 . In 6 of 10 calves, the serum concentration-time profile was characterized by two peaks, the first occurring within 1 hr and the second between 1.5 and 4 hr.
Oxytetracycline penetration into exudate and transudate was quantitatively similar. Exudate and transudate C max were significantly lower than peak serum concentration (p < .01). However, from 32-hr to 120-hr oxytetracycline concentrations in tissue cage fluids were greater than those in serum (Figure 2 ). Numerically lower AUC 0-last values were obtained in exudate and transudate, 125 μg hr/ml and 105 μg hr/ml, respectively, compared to 153 μg hr/ml in serum, but these differences were not statistically significant (p > .05). For all three fluids, the percentage of AUC 0-∞ occurring after the last sampling time (120 hr) was <12%. Mean residence times were similar in exudate and transudate, and both were significantly longer (p < .01) than MRT in serum (Table 1) .
| PK-PD integration
Pharmacokinetic-pharmacodynamic integration established the surrogates, C max /MIC, T > MIC, AUC 0-24 hr /MIC (first 24 hr) and AUC 0-∞ / MIC, derived from in vivo oxytetracycline serum concentrations in the PK study and in vitro MICs of the test organisms measured in both MHB and serum. Data are presented in Appendix S1.
Average oxytetracycline concentrations (C ave ) in serum in the PK study, over four successive 24-hr time periods, from 0-24 to 72-96 hr, were determined. Based on MHB MICs, C ave /MIC ratios exceeded 1.5:1 up to 72-96 hr, whereas based on serum MICs, the ratios were less than 1:1 for all four time intervals ( Predicted doses for both single-dose administration and dosing at steady-state are presented in For P. multocida and a bacteriostatic action with single-dose administration and a duration of action of 48 hr, 50 and 90% TARs were 314 and 682 mg/kg, based on serum MICs (Table 5) . However, based on broth MICs, corresponding values were much lower, 11.5 and 24.9 mg/kg (Appendix S2). As for M. haemolytica, for a bactericidal action, higher doses were predicted.
| PK-PD modelling and dosage determination
As expected from the accumulation ratio over a dosing interval of 48 hr (approximately 1.5-1.6), the predicted alternate day T A B L E 2 Average serum oxytetracycline concentration (C ave )/ MIC ratios for four consecutive 24-hr periods after oxytetracycline administration (n = 10 calves) T A B L E 3 PK-PD modelling of in vitro time-kill data (mean and SD, n = 6 unless stated) for three levels of growth inhibition of M. haemolytica by oxytetracycline in MHB and serum T A B L E 4 PK-PD modelling of in vitro time-kill data (mean and SD, n = 6 unless stated) for three levels of inhibition of P. multocida by oxytetracycline in MHB and serum doses, at steady-state, were lower than those calculated for the single-dose approach. Thus, based on serum MICs and a bacteriostatic action, TARs of 50 and 90% were 125 and 141 mg/kg for M. haemolytica and 200 and 424 mg/kg for P. multocida (Table 5) .
Much lower doses were predicted for alternate day administration at steady-state based on broth MICs. Predicted doses were 4.97 and 5.58 mg/kg for M. haemolytica for 50 and 90% TARs for bacteriostasis. Corresponding predicted doses were 7.28 and 15.4 mg/kg for P. multocida (Appendix S2).
| DISCUSSION
| Pharmacokinetics
Tissue cages comprise hollow perforated devices, which become surrounded by and partially infiltrated with granulation tissue, when implanted subcutaneously (Higgins, Lees, & Wright, 1984; Lees, Higgins, Sedgwick, & May, 1987) . When using tissue cages to study the extravascular distribution of drugs, it is important to recognize that the time courses of penetration into and removal from tissue cage fluid are model (shape) dependent. Thus, solute (including drug) penetration and elimination rates vary with each drug/solute, tissue cage age, size, location and geometry, most notably with surface area: volume ratio of the cage.
Intracaveal injection of the mild irritant carrageenan provides an ethical means of generating and readily sampling inflammatory exudate (Lees et al., 1987; Sidhu et al., 2003) . The tissue cage model therefore provides a means of studying a possible matrix effect when investigating ex vivo PD of AMDs not only in serum (which is not the ultimate site of AMD action) but also in matrices that better reflect composition of the AMD biophase for extracellular pathogens namely exudate (in the presence of inflammation as appropriate for curative treatment) and transudate (in the absence of inflammation as appropriate for prophylaxis and for metaphylaxis) Brentnall et al., 2012; Sidhu et al., 2010) . The tissue cage model thus facilitates comparison of PD data with findings generated in nonbiological growth matrices, such as MHB.
The serum concentration-time profile of oxytetracycline, using a high strength depot formulation, was similar to those reported in earlier studies with the same dosage of 20 mg/kg administered intramuscularly (Brentnall et al., 2012; Davey, Ferber, & Kaye, 1985; El Korchi, Prats, Arboix, & Perez, 2001; Mestorino, Marino Hernandez, Marchetti, & Errecalde, 2007; Nouws & Vree, 1983; Toutain & Raynaud, 1983) . Toutain and Raynaud (1983) reported that oxytetracycline absorption occurred in two phases: the first was rapid and the second slower phase led to a flip-flop PK profile.
The findings in this study, likewise, indicated rapid initial absorption and, in most animals, two early concentration peaks. It is very likely that, as in previous studies, the PK profile was flip-flop, with slow passage of the drug into solution at the injection site (Nouws et al., 1990) . Thus, in the previous studies and the present investigation, the terminal half-life, representing a slow absorption phase, was prolonged, ranging from 21.7 hr (Brentnall et al., 2012) to 30.1 hr (this investigation).
| PK-PD integration
The underlying causes of marked serum/MHB differences in potency of oxytetracycline, as reflected in MICs, have not been established.
Approximately twofold higher MICs in serum compared to MHB would be anticipated from the binding of oxytetracycline to serum proteins, which was shown to be 53% of total concentration in calves (Lees et al., 2016) . This is well short of the approximately 25-fold differences in MIC obtained experimentally (Lees et al., 2016) . Serum/ TAR, target attainment rate (probability for the serum concentration to exceed the PD end point for efficacy). Dosages were computed by Monte Carlo simulation using Equations 5 and 8 for steady-state and loading dose approaches, respectively, with (i) wild-type MIC distributions ranging from 0.25 to 2 μg/ml (n = 498) for P. multocida and 0.25-1 μg/ml (n = 481) for M. haemolytica determined by the Turnidge method; (ii) average AUC 0-24 hr /MIC e /24 hr = κ PD calculated for experimentally obtained bacteriostatic or bactericidal action (data from three or four strains); (iii) individual animal clearance and elimination rate constant (k 10 ) empirical distributions obtained for 10 healthy calves (present study) receiving the dose recommended by the manufacturer (20 mg/kg); (iv) f u the average oxytetracycline free fraction determined experimentally; and (v) the difference in MIC broth: serum ratio of 27.4:1 for P. multocida and 25.2:1 for M.haemolytica.
T A B L E 5 Predicted dosage (mg/kg) based on PK-PD modelling and Monte Carlo simulation of oxytetracycline data in serum using either steady-state or single dose (long duration of action) for computation with application of serum: broth MIC ratio MHB MIC (μg/ml) ratios were 6.75/0.25 (P. multocida) and 5.46/0.22
Mean serum MIC of M. haemolytica in this study was 5.46 μg/ ml. Esaki et al. (Esaki et al., 2005) serum scaling factor equates to >200 μg/ml for a significant proportion of field isolates.
The most appropriate PK/PD index to correlate with clinical efficacy depends on AMD terminal half-life; when this is relatively long, as for oxytetracycline in this study, AUC/MIC ratio is the index of choice (Nielsen & Friberg, 2013) . From the present data, the predicted clinical efficacy of oxytetracycline in vivo would be at most slight, insofar as it depends on both serum MIC and a direct inhibitory action on cell division. This conclusion was confirmed in a previous study by ex vivo findings; time-kill curves obtained with near maximum oxytetracycline concentrations in serum produced little or no growth inhibition of M. haemolytica and P. multocida isolates (Lees et al., 2016) . 
| PK/PD modelling
| Dosage prediction
Predicted (TAR) doses for oxytetracycline were calculated using scientific literature values for oxytetracycline MIC distributions together with data from this study for PK variables (Cl/F and f u ) and PK-PD breakpoints (AUC 0-24 hr /MIC e ). Fifty and 90% TAR dosages were calculated for steady-state and for single doses with a duration of action of 48 hr in both cases. All doses based on oxytetracycline MICs in serum were some 25-fold greater than doses based on MICs measured by the CLSI method in broth. For example, for single dosing and a period of 48 hr, the 90% TAR dosages for a bactericidal action (serum first, broth second) were 452 and 17.9 mg/kg (M. haemolytica) and 1,523 and 55.6 mg/kg (P. multocida).
Despite these considerations, it should be noted that oxytetracycline is usually classified as a bacteriostat and it is therefore assumed that efficacy will generally require the support of the body's natural defence mechanisms. Moreover, the challenge presented to the killing action of oxytetracycline in our time-kill experiments, with a starting inoculum count of the order of 10 7 cfu/ml, may be described as heavy, in comparison with bacterial load in clinical subjects with natural infection. It is also approximately 100-fold higher than the inoculum count recommended for AMD PD studies by CLSI, the higher count being deliberately selected to represent a heavy load in this study. In those cases where infection is mild and treated early, when biophase bacterial counts would be predicted to be low, as discussed by Mouton et al. (Mouton et al., 2011 ), Martinez et al. (Martinez et al., 2012 and Papich (Papich, 2013 (Papich, , 2014 for some 30%-50% of isolates (Portis, Lindeman, Johansen, & Stoltman, 2012) .
These data suggest that epidemiological information obtained for tetracycline might also be relevant for oxytetracycline. In this regard, de Jong et al. (de Jong et al., 2014) reported for EU tetracycline isolates essentially unimodal distributions for P. multocida and M. haemolytica of bovine origin; 94 and 84% of isolates, respectively, had MICs of 2 μg/ml or less, which is consistent with a wild-type distribution for P. multocida and M. haemolytica. This could be explained by the fact that these authors collected samples from diseased or recently deceased calves not exposed to AMD treatment for at least 15 days prior to sampling, that is having not been subjected to any selective pressure with an enrichment of less susceptible pathogens to oxytetracycline. We are not aware of any recent data of EU origin for oxytetracycline against these species but EUCAST provides a cut-off value for M. haemolytica for tetracycline of 2 μg/ml and the EUCAST distribution for oxytetracycline for P. multocida also suggests a cut-off of 2 μg/ml. The MIC distribution of field strains represents isolates that might be submitted to the laboratory in cases of failure with first intention treatment, and for this reason, the Monte Carlo simulations were performed using only the wild-type subpopulation. It should be noted that Epidemiological Cut-Off values are useful tools for epidemiologists but clinicians require clinical breakpoints.
| Clinical efficacy of oxytetracycline
In early field studies, usually with small animal numbers, oxytetracycline was reported as effective for metaphylaxis and therapy in cases of calf pneumonia, as assessed by resolution or improvement of clinical signs (Deleforge, Thomas, Davot, & Boisrame, 1994; Laven & Andrews, 1991; Morck et al., 1993; Musser, Mechor, Grohn, Dubovi, & Shin, 1996) . analysis to compare the efficacy of 12 AMD treatments versus a nonactive control for bovine respiratory disease in beef cattle. They concluded that oxytetracycline had the lowest ranking (11.24 with a credibility interval of 9-13) close to the ranking of the nonactive control (12.52 with a credibility interval of 11-13). They also drew attention to the lack of recent data for oxytetracycline.
These clinical findings and the present data focus consideration on possible mechanisms of action of oxytetracycline, in addition to its direct growth inhibiting action, as discussed previously (Brentnall et al., 2012; Lees et al., 2015) . In summary, it is concluded, that oxytetracycline doses for a direct killing action, based on PK/PD relationships and using serum MIC data, are not achievable in clinical use. Moreover, it is unlikely that antimicrobial sensitivity testing for this drug, against the calf pneumonia pathogens, M. haemolytica and P. multocida, can be used to predict clinical efficacy.
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